title: Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer.
abstract: OBJECTIVE
  To determine the feasibility of docetaxel-cisplatin combination therapy compared with docetaxel-carboplatin combination therapy as first-line chemotherapy for patients with ovarian cancer.
  
  
  METHODS
  Fifty patients with International Federation of Gynecology and Obstetrics stage Ic-IV ovarian cancer who underwent primary surgery were randomly assigned to receive treatment with docetaxel-cisplatin (n = 23) or docetaxel-carboplatin (n = 27). Docetaxel 70 mg/m2 and cisplatin 60 mg/m2 or carboplatin to an area under the curve of 5 were administered consecutively on Day 1 of a 3-week cycle, for 3 cycles in patients with stage Ic-II cancer and for over 5 cycles in patients with stage III-IV cancer. Patients were evaluated for treatment-related toxicity in each cycle using the National Cancer Institute Common Toxicity Criteria version 2.0.
  
  
  RESULTS
  Five patients (2 in the docetaxel-cisplatin arm and 3 in the docetaxel-carboplatin arm) discontinued the treatment at the end of the second course of chemotherapy because of apparent disease progression; however, no patients came off the protocol therapy because of treatment-related toxicity. Overall, 103 cycles of docetaxel-cisplatin treatment and 130 cycles of docetaxel-carboplatin treatment were delivered. The major toxicity was neutropenia in both regimens. The total incidence of grades 3 and 4 neutropenia was 83% (19/23) in the docetaxel-cisplatin arm and 96% (26/27) in the docetaxel-carboplatin arm. The incidence of grade 4 neutropenia was significantly lower in the docetaxel-cisplatin arm [39% (9/23) versus 74% (20/27)].
  
  
  CONCLUSIONS
  Docetaxel-cisplatin combination therapy may be feasible as first-line chemotherapy for patients with ovarian cancer.
authors.affiliation: Department of Obstetrics and Gynecology, Tottori Prefectural Central Hospital, 730 Ezu, Tottori 680-0901, Japan. minagawa-y@pref.tottori.jp
authors.forename: Yukihisa
authors.initials: Y
authors.lastname: Minagawa
authors.forename: Junzo
authors.initials: J
authors.lastname: Kigawa
authors.forename: Yasunobu
authors.initials: Y
authors.lastname: Kanamori
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Itamochi
authors.forename: Naoki
authors.initials: N
authors.lastname: Terakawa
authors.forename: Makoto
authors.initials: M
authors.lastname: Okada
authors.forename: Fuminori
authors.initials: F
authors.lastname: Kitada
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D016190:Carboplatin; D002945:Cisplatin